Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
Completed
UCB Pharma
Phase 2
2005-10-01
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo,
administered during 12 weeks, to patients suffering from moderate to severe chronic plaque
psoriasis, extended by a 12 to 24 week follow-up.
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
Completed
UCB Pharma
Phase 4
2007-12-01
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and
4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and
16. At Wk 18 patients will be grouped as responders or non-responders based on results of the
ACR20 at Week 16.
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Completed
UCB Pharma
Phase 3
2008-07-01
This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab
pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
Completed
Centocor, Inc.
Phase 2
2008-12-01
A medical research study in adult patients who have moderate to severe Crohn's disease
designed to determine whether or not treatment with an experimental drug called ustekinumab
(or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of
Crohn's disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
